Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Changes in Stockholders??? Deficit (Unaudited)

v3.22.2.2
Consolidated Statements of Changes in Stockholders’ Deficit (Unaudited) - USD ($)
Common Stock
Stock payable
Additional Paid-in Capital
Total Accumulated Deficit
Mezzanine Equity
Total
Balance at Dec. 31, 2020 $ 44,727,171 $ (97,322,784) $ 40,070,108 $ (52,595,613)
Balance (in Shares) at Dec. 31, 2020 4,298          
Stock based compensation 5,092,248 5,092,248
Issuance of Common Shares $ 1 23,450   23,451
Issuance of Common Shares (in Shares) 4,700          
Preferred Stock conversion into common stock $ 6   40,070,101   (40,070,108) 40,070,107
Preferred Stock conversion into common stock (in Shares) 618,687          
Notes payable and accrued interest conversion into common stock $ 6   10,639,610     10,639,616
Notes payable and accrued interest conversion into common stock (in Shares) 571,621          
Preferred Stock C exchange for Nanomix Common Stock $ (13)   (14,670,620)   14,670,633 (14,670,633)
Preferred Stock C exchange for Nanomix Common Stock (in Shares) (1,199,306)          
Merge with Boston Therapeutics $ 5,300   (3,870,989)   963,964 (3,865,689)
Merge with Boston Therapeutics (in Shares) 5,300,084          
Loss on debt modification     2,385,204     2,385,204
Net loss   (4,791,552)   (4,791,552)
Balance at Jun. 30, 2021 $ 5,300 84,396,175 (102,114,336) 15,634,597 (17,712,861)
Balance (in Shares) at Jun. 30, 2021 5,300,084          
Balance at Dec. 31, 2021 $ 5,300 20,375 85,092,094 (106,787,817) 15,634,597 (21,670,048)
Balance (in Shares) at Dec. 31, 2021 5,300,084          
Fractional shares rounding $ 3   (3)      
Fractional shares rounding (in Shares) 2,757          
Stock based compensation 52,635     $ 52,635
Preferred Stock conversion into common stock (in Shares)           1,000
Warrants issued with notes     1,651,480     $ 1,651,480
Issuance of Series D Shares       (100,000) 600,000 (100,000)
Change in number of warrants pursuant by antidilution issuance     63,172 (63,172)    
Preferred Stock B conversion into common stock $ 5,572   958,392   (963,964) 963,964
Preferred Stock B conversion into common stock (in Shares) 5,572,045          
Preferred Stock C conversion into common stock $ 35,445 (20,375) 14,573,612 (14,588,683) 14,588,682
Preferred Stock C conversion into common stock (in Shares) 35,445,919          
Secured Promissary Notes converted into common stock $ 112   130,888     131,000
Secured Promissary Notes converted into common stock (in Shares) 111,803          
Services compensated by stock issuance $ 32   49,968     50,000
Services compensated by stock issuance (in Shares) 31,847          
Stock options exercised   2,600       2,600
Net loss   (5,500,971)   (5,500,971)
Balance at Jun. 30, 2022 $ 46,464 $ 2,600 $ 102,572,238 $ (112,451,960) $ 681,950 $ (9,830,658)
Balance (in Shares) at Jun. 30, 2022 46,464,455